The prevalence and correlates of psychiatric comorbidity in individuals with complicated grief
Abstract
Background
Complicated grief (CG), variously called pathological or traumatic grief, is a debilitating syndrome that is not currently included in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) nomenclature. One issue that remains under debate is whether this condition can be clearly distinguished from other psychiatric disorders, such as major depression and posttraumatic stress disorder, with which CG frequently coexists.
Methods
Using a structured clinical interview for CG and the Structured Clinical Interview for DSM-IV, trained experienced raters conducted careful diagnostic assessments of individuals seeking treatment of bereavement-related distress. All study participants met criteria for a current CG syndrome. Liberal criteria were used to diagnose DSM-IV disorders, making no attempt to decide if symptoms could be explained by grief.
Results
Of 206 who met the criteria for CG, 25% had no evidence of a current DSM-IV Axis I disorder. When present, psychiatric comorbidity was associated with significantly greater severity of grief; however, even after adjustment for the presence of comorbidity, severity of CG symptoms was associated with greater work and social impairment.
Limitations
It is likely that our study underestimated the rate of CG without comorbidity because fewer DSM diagnoses would have been made if a judgment about grief had been taken into consideration.
Conclusions
Our data provide further support for the need to identify CG as a psychiatric disorder.
To access this article, please choose from the options below
Naomi Simon is a consultant for Paramount Biosciences and is on the Speaker's Bureau for Continuing Medical Education and other presentations for Forest Laboratories, Janssen, Lilly, Pfizer, Sepracor and UCB Pharma. Dr Simon has participated in clinical trials sponsored by Cephalon, Janssen, UCB Pharma, and Sepracor. Dr Simon has received investigator-initiated grants from AstraZeneca, Cephalon, Forest Laboratories, GlaxoSmithKline, Pfizer, Lilly, the National Institute of Mental Health, and the National Alliance for Research of Schizophrenia and Depression. Katherine Shear is a consultant for Pfizer and receives research grant funding from Forest Laboratories. Charles Reynolds III receives research support in the form of pharmaceutical supplies for National Institutes of Health–sponsored work from GlaxoSmithKline, Forest, Pfizer, Lilly, and Bristol-Myers Squibb. Ellen Frank is a consultant for Pfizer, Eli Lilly, and Novartis. Dr Frank receives grant support from the National Institute of Mental Health and the Forest Research Institute and serves on the advisory board for Pfizer, Eli Lilly, and Servier. Nadine Melhem has received a travel award from the American Foundation for Suicide Prevention. All other authors declare that they have no conflicts of interest.
PII: S0010-440X(07)00058-2
doi:10.1016/j.comppsych.2007.05.002
© 2007 Elsevier Inc. All rights reserved.
